Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.55 USD
Change Today -0.15 / -1.18%
Volume 763.2K
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VNDA) Snapshot

Open
$12.75
Previous Close
$12.70
Day High
$12.88
Day Low
$12.41
52 Week High
12/26/14 - $15.51
52 Week Low
10/13/14 - $8.34
Market Cap
530.7M
Average Volume 10 Days
821.4K
EPS TTM
$0.08
Shares Outstanding
42.3M
EX-Date
--
P/E TM
156.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for VANDA PHARMACEUTICALS INC (VNDA)

vanda pharmaceuticals inc (VNDA) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VNDA) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company’s products include HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also include Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

105 Employees
Last Reported Date: 07/31/15
Founded in 2002

vanda pharmaceuticals inc (VNDA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $580.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2014.

vanda pharmaceuticals inc (VNDA) Key Developments

Vanda Pharmaceuticals, Inc. Reports Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Sales Guidance for the Full Year 2015

Vanda Pharmaceuticals, Inc. reported consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $27,582,000 against $10,862,000 a year ago. Loss from operations was $5,458,000 against $21,606,000 a year ago. Net loss was $5,386,000 or $0.13 per basic and diluted share against $21,575,000 or $0.64 per basic and diluted share a year ago. Non-GAAP net loss was $376,000 or $0.01 per basic and diluted share compared to $27,279,000 or $0.81 per basic and dilute share a year ago. Non-GAAP total revenues were $27,582,000 compared to $3,098,000 a year ago. For the six months, the company reported total revenues of $49,732,000 against $20,005,000 a year ago. Loss from operations was $15,751,000 against $48,184,000 a year ago. Net loss was $15,607,000 or $0.37 per basic and diluted share diluted against $48,108,000 or $1.42 per basic and diluted share a year ago. Net cash used in operating activities was $60,569,000 against $17,168,000 a year ago. Non-GAAP net loss was $4,508,000 or $0.11 per basic and diluted share compared to $59,306,000 or $1.76 per basic and dilute share a year ago. Non-GAAP total revenues were $49,732,000 compared to $4,789,000 a year ago. For the year 2015, the company expected net product sales from both HETLIOZ and Fanapt of between $100 million and $115 million, compared to prior guidance of $95 million to $110 million. The company expected HETLIOZ net product sales of between $40 million to $45 million. The company expected Fanapt net product sales of between $60 million to $70 million, compared to prior guidance of $55 million to $65 million.

Vanda Pharmaceuticals, Inc. to Report Q2, 2015 Results on Jul 29, 2015

Vanda Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 29, 2015

Vanda Pharmaceuticals, Inc., Q2 2015 Earnings Call, Jul 29, 2015

Vanda Pharmaceuticals, Inc., Q2 2015 Earnings Call, Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $12.55 USD -0.15

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,385 GBp +43.00
Bristol-Myers Squibb Co $64.84 USD -0.50
Eli Lilly & Co $84.05 USD -0.09
Pernix Therapeutics Holdings Inc $4.90 USD -0.05
Sanofi €98.17 EUR -0.47
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings 9.8x
Price/Sales 6.7x
Price/Book 3.6x
Price/Cash Flow 8.8x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit www.vandapharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.